AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 | >>
Results: 1-25/101
PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER
Authors: VOGELZANG NJ MANI S SCHILSKY RL ANSARI RH TABER D RHINEHART SN GARCIA JC MEYER SC MICK R BROCKSTEIN BE STADLER WM RATAIN MJ VOKES EE
Citation: Nj. Vogelzang et al., PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER, Clinical cancer research, 4(4), 1998, pp. 929-934
PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER
Authors: VOGELZANG NJ MANI S SCHILSKY RL ANSARI RH TABER D RHINEHART SN GARCIA JC MEYER SC MICK R BROCKSTEIN BE STADLER WM RATAIN MJ VOKES EE
Citation: Nj. Vogelzang et al., PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER, Clinical cancer research, 4(4), 1998, pp. 929-934
PHARMACOGENETICS AND CANCER-CHEMOTHERAPY
Authors: IYER L RATAIN MJ
Citation: L. Iyer et Mj. Ratain, PHARMACOGENETICS AND CANCER-CHEMOTHERAPY, European journal of cancer, 34(10), 1998, pp. 1493-1499
GENERAL OVERVIEW - WHAT CAN WE LEARN FROM THE DRUG DEVELOPMENT OF NONCANCER DRUGS
Authors: RATAIN MJ
Citation: Mj. Ratain, GENERAL OVERVIEW - WHAT CAN WE LEARN FROM THE DRUG DEVELOPMENT OF NONCANCER DRUGS, Annals of oncology, 9, 1998, pp. 17-17
GLUCURONIDATION OF TAS-103 BY URIDINE-DIPHOSPHATE GLUCURONOSYLTRANSFERASE (UGT) ISOFORMS 1A1 AND 2 - POSSIBLE IMPLICATION OF TAS-103 TOXICITY IN GILBERTS-SYNDROME
Authors: IYER L MORTELL MA AZUMA R YAMAMOTO Y RATAIN MJ
Citation: L. Iyer et al., GLUCURONIDATION OF TAS-103 BY URIDINE-DIPHOSPHATE GLUCURONOSYLTRANSFERASE (UGT) ISOFORMS 1A1 AND 2 - POSSIBLE IMPLICATION OF TAS-103 TOXICITY IN GILBERTS-SYNDROME, Annals of oncology, 9, 1998, pp. 230-230
A PHASE-II STUDY OF 9-AMINOCAMPTOTHECIN IN ADVANCED NONSMALL CELL LUNG-CANCER
Authors: VOKES EE ANSARI RH MASTERS GA HOFFMAN PC KLEPSCH A RATAIN MJ SCIORTINO DF LAD TE KRAUSS S FISHKIN PAS GOLOMB HM
Citation: Ee. Vokes et al., A PHASE-II STUDY OF 9-AMINOCAMPTOTHECIN IN ADVANCED NONSMALL CELL LUNG-CANCER, Annals of oncology, 9, 1998, pp. 253-253
A PHASE-1 STUDY OF RALTITREXED (TOMUDEX(R)) AND PACLITAXEL
Authors: VOKES EE BERTUCCI D VOGELZANG NJ MANI S LOWERY C RATAIN MJ
Citation: Ee. Vokes et al., A PHASE-1 STUDY OF RALTITREXED (TOMUDEX(R)) AND PACLITAXEL, Annals of oncology, 9, 1998, pp. 462-462
SINGLE AND MULTIPLE-DOSE PHARMACOKINETICS OF SPI-77 (STEALTH(R) LIPOSOMAL CISPLATIN) GIVEN EVERY 3 WEEKS IN PATIENTS WITH ADVANCED CANCER
Authors: AMANTEA MA DEMARIO MD SCHWARTZ G VOGELZANG NJ TONDA M PENDYALA L RATAIN MJ
Citation: Ma. Amantea et al., SINGLE AND MULTIPLE-DOSE PHARMACOKINETICS OF SPI-77 (STEALTH(R) LIPOSOMAL CISPLATIN) GIVEN EVERY 3 WEEKS IN PATIENTS WITH ADVANCED CANCER, Annals of oncology, 9, 1998, pp. 465-465
A PHASE-I STUDY OF LIPOSOME-FORMULATED CISPLATIN (SPI-77(R)) GIVEN EVERY 3 WEEKS IN PATIENTS WITH ADVANCED CANCER
Authors: DEMARIO MD VOGELZANG NJ JANISCH L HUMPHRISS E MANI S TONDA M AMANTEA MA RATAIN MJ PENDYALA L
Citation: Md. Demario et al., A PHASE-I STUDY OF LIPOSOME-FORMULATED CISPLATIN (SPI-77(R)) GIVEN EVERY 3 WEEKS IN PATIENTS WITH ADVANCED CANCER, Annals of oncology, 9, 1998, pp. 466-466
PHASE-I STUDY OF CEP-2563 DIHYDROCHLORIDE (CEP-2563), A TYROSINE KINASE INHIBITOR, IN PATIENTS WITH SOLID TUMORS
Authors: MAUER AM VOGELZANG NJ JANISH L MANI S SAMARA E RATAIN MJ
Citation: Am. Mauer et al., PHASE-I STUDY OF CEP-2563 DIHYDROCHLORIDE (CEP-2563), A TYROSINE KINASE INHIBITOR, IN PATIENTS WITH SOLID TUMORS, Annals of oncology, 9, 1998, pp. 489-489
PHASE-I STUDY OF THE DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) INHIBITOR ENILURACIL (GW776C85) AND ORAL 5-FU WITH CONCOMITANT RADIOTHERAPY (XRT) FOR RECURRENT OR ADVANCED HEAD AND NECK-CANCER (HNC)
Authors: VOKES EE HUMERICKHOUSE R DOLAN E BROCKSTEIN B HARAF D STENSON K KIES M SULZEN L HOUSE L RATAIN MJ
Citation: Ee. Vokes et al., PHASE-I STUDY OF THE DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) INHIBITOR ENILURACIL (GW776C85) AND ORAL 5-FU WITH CONCOMITANT RADIOTHERAPY (XRT) FOR RECURRENT OR ADVANCED HEAD AND NECK-CANCER (HNC), Annals of oncology, 9, 1998, pp. 597-597
POPULATION PHARMACOKINETIC DETERMINATION OF THE EFFECT OF FOOD ON THEPHARMACOKINETICS OF ORAL 5-FLUOROURACIL (FU) AND ENILURACIL (776C85, 776)
Authors: SHEPARD DR MANI S JANISCH L FLEMING GF SCHILSKY RL RATAIN MJ
Citation: Dr. Shepard et al., POPULATION PHARMACOKINETIC DETERMINATION OF THE EFFECT OF FOOD ON THEPHARMACOKINETICS OF ORAL 5-FLUOROURACIL (FU) AND ENILURACIL (776C85, 776), Annals of oncology, 9, 1998, pp. 600-600
PHASE-I STUDY OF ZD9331 USING A 5-DAY SHORT INFUSION SCHEDULE
Authors: RATAIN MJ GOH BC SMITH R BERTUCCI D MANI S VOGELZANG NJ SCHILSKY RL HUTCHISON M DOUGLASS E
Citation: Mj. Ratain et al., PHASE-I STUDY OF ZD9331 USING A 5-DAY SHORT INFUSION SCHEDULE, Annals of oncology, 9, 1998, pp. 616-616
A PHASE-I TRIAL OF CONTINUOUS-INFUSION 5-FLUOROURACIL AND WEEKLY GEMCITABINE - UPDATED RESULTS OF AN ACTIVE COMBINATION FOR RENAL-CELL, HEPATOCELLULAR AND COLON-CARCINOMA
Authors: MANI S GORDON G VOGELZANG NJ BERTUCCI D SCHILSKY RL STADLER WM RATAIN MJ
Citation: S. Mani et al., A PHASE-I TRIAL OF CONTINUOUS-INFUSION 5-FLUOROURACIL AND WEEKLY GEMCITABINE - UPDATED RESULTS OF AN ACTIVE COMBINATION FOR RENAL-CELL, HEPATOCELLULAR AND COLON-CARCINOMA, Annals of oncology, 9, 1998, pp. 632-632
A PHASE-II STUDY OF 9-AMINOCAMPTOTHECIN IN ADVANCED NON-SMALL-CELL LUNG-CANCER
Authors: VOKES EE ANSARI RH MASTERS GA HOFFMAN PC KLEPSCH A RATAIN MJ SCIORTINO DF LAD TE KRAUSS S FISHKIN PAS GOLOMB HM
Citation: Ee. Vokes et al., A PHASE-II STUDY OF 9-AMINOCAMPTOTHECIN IN ADVANCED NON-SMALL-CELL LUNG-CANCER, Annals of oncology, 9(10), 1998, pp. 1085-1090
BODY-SURFACE AREA AS A BASIS FOR DOSING OF ANTICANCER AGENTS - SCIENCE, MYTH, OR HABIT
Authors: RATAIN MJ
Citation: Mj. Ratain, BODY-SURFACE AREA AS A BASIS FOR DOSING OF ANTICANCER AGENTS - SCIENCE, MYTH, OR HABIT, Journal of clinical oncology, 16(7), 1998, pp. 2297-2298
STUDY OF COHORT-SPECIFIC CONSENT AND PATIENT CONTROL IN PHASE-I CANCER TRIALS
Authors: DAUGHERTY CK RATAIN MJ MINAMI H BANIK DM VOGELZANG NJ STADER WM SIEGLER M
Citation: Ck. Daugherty et al., STUDY OF COHORT-SPECIFIC CONSENT AND PATIENT CONTROL IN PHASE-I CANCER TRIALS, Journal of clinical oncology, 16(7), 1998, pp. 2305-2312
ORAL CHEMOTHERAPY - RATIONALE AND FUTURE-DIRECTIONS
Authors: DEMARIO MD RATAIN MJ
Citation: Md. Demario et Mj. Ratain, ORAL CHEMOTHERAPY - RATIONALE AND FUTURE-DIRECTIONS, Journal of clinical oncology, 16(7), 1998, pp. 2557-2567
PHASE-II TRIAL OF PACLITAXEL AND TOPOTECAN WITH GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT IN STAGE-IV BREAST-CANCER
Authors: FLEMING GF KUGLER JW HOFFMAN PC ANSARI R BITRAN JD KLEPSCH A MALONE D FASANMADE AA RATAIN MJ VOKES EE
Citation: Gf. Fleming et al., PHASE-II TRIAL OF PACLITAXEL AND TOPOTECAN WITH GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT IN STAGE-IV BREAST-CANCER, Journal of clinical oncology, 16(6), 1998, pp. 2032-2037
O-6-BENZYLGUANINE IN HUMANS - METABOLIC, PHARMACOKINETIC, AND PHARMACODYNAMIC FINDINGS
Authors: DOLAN ME ROY SK FASANMADE AA PARAS PR SCHILSKY RL RATAIN MJ
Citation: Me. Dolan et al., O-6-BENZYLGUANINE IN HUMANS - METABOLIC, PHARMACOKINETIC, AND PHARMACODYNAMIC FINDINGS, Journal of clinical oncology, 16(5), 1998, pp. 1803-1810
PHASE-I AND PHARMACOKINETIC TRIAL OF PACLITAXEL IN PATIENTS WITH HEPATIC-DYSFUNCTION - CANCER AND LEUKEMIA GROUP-B-9264
Authors: VENOOK AP EGORIN MJ ROSNER GL BROWN TD JAHAN TM BATIST G HOHL R BUDMAN D RATAIN MJ KEARNS CM SCHILSKY RL
Citation: Ap. Venook et al., PHASE-I AND PHARMACOKINETIC TRIAL OF PACLITAXEL IN PATIENTS WITH HEPATIC-DYSFUNCTION - CANCER AND LEUKEMIA GROUP-B-9264, Journal of clinical oncology, 16(5), 1998, pp. 1811-1819
PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF ENILURACIL PLUS FLUOROURACIL IN PATIENTS WITH ADVANCED CANCER
Authors: SCHILSKY RL HOHNEKER J RATAIN MJ JANISCH L SMETZER L LUCAS VS KHOR SP DIASIO R VONHOFF DD BURRIS HA
Citation: Rl. Schilsky et al., PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF ENILURACIL PLUS FLUOROURACIL IN PATIENTS WITH ADVANCED CANCER, Journal of clinical oncology, 16(4), 1998, pp. 1450-1457
PHASE-I STUDY OF CONCOMITANT CHEMORADIOTHERAPY WITH PACLITAXEL, FLUOROURACIL, AND HYDROXYUREA WITH GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT FOR PATIENTS WITH POOR-PROGNOSIS CANCER OF THE HEAD AND NECK
Authors: BROCKSTEIN B HARAF DJ STENSON K FASANMADE A STUPP R GLISSON B LIPPMAN SM RATAIN MJ SULZEN L KLEPSCH A WEICHSELBAUM RR VOKES EE
Citation: B. Brockstein et al., PHASE-I STUDY OF CONCOMITANT CHEMORADIOTHERAPY WITH PACLITAXEL, FLUOROURACIL, AND HYDROXYUREA WITH GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT FOR PATIENTS WITH POOR-PROGNOSIS CANCER OF THE HEAD AND NECK, Journal of clinical oncology, 16(2), 1998, pp. 735-744
A FLAT DOSE FOR ALL ADULT [SIC] PATIENTS - IN REPLY
Authors: RATAIN MJ
Citation: Mj. Ratain, A FLAT DOSE FOR ALL ADULT [SIC] PATIENTS - IN REPLY, Journal of clinical oncology, 16(11), 1998, pp. 3715-3715
PHASE-I AND PHARMACOLOGICAL STUDY OF CONTINUOUS-INFUSION TOPOTECAN INCOMBINATION WITH CISPLATIN IN PATIENTS WITH ADVANCED CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY
Authors: LILENBAUM RC MILLER AA BATIST G BERNARD S HOLLIS DR ROSNER GL EGORIN MJ SCHILSKY RL RATAIN MJ
Citation: Rc. Lilenbaum et al., PHASE-I AND PHARMACOLOGICAL STUDY OF CONTINUOUS-INFUSION TOPOTECAN INCOMBINATION WITH CISPLATIN IN PATIENTS WITH ADVANCED CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY, Journal of clinical oncology, 16(10), 1998, pp. 3302-3309
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>